29. December 2020 - Portfolio News
GNA Biosolutions Receives Emergency Use Authorization from German Health Authority BfArM for Rapid Molecular SARS-CoV-2 Batch Testing System
![](https://www.shs-capital.eu/wp-content/uploads/2021/01/GNA_Octea-1024x684.png)
German molecular diagnostics startup GNA Biosolutions has received Emergency Use Authorization (Sonderzulassung) from the German Federal Institute for Drugs and Medical Devices (BfArM) for the GNA Octea SARS-CoV-2 Test System. The new technology developed by GNA Biosolutions enables decentralized COVID-19 rapid tests in approximately 40 minutes without sacrificing sensitivity.